PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
738.04%
R&D growth while RVPH reduces spending. John Neff would investigate strategic advantage.
40.95%
G&A growth while RVPH reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
-9.94%
Other expenses reduction while RVPH shows 0.00% growth. Joel Greenblatt would examine efficiency.
178.81%
Operating expenses growth while RVPH reduces costs. John Neff would investigate differences.
178.81%
Total costs growth while RVPH reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
-9.94%
D&A reduction while RVPH shows 0.00% growth. Joel Greenblatt would examine efficiency.
-184.06%
EBITDA decline while RVPH shows 5.85% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-178.81%
Operating income decline while RVPH shows 7.11% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-185.77%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-184.01%
Pre-tax income decline while RVPH shows 5.94% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-184.01%
Net income decline while RVPH shows 5.90% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-184.12%
EPS decline while RVPH shows 7.69% growth. Joel Greenblatt would examine position.
-184.12%
Diluted EPS decline while RVPH shows 7.69% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.